Estoril, Portugal–
In recognition of her personal contribution and role in leading The Max Foundation in increasing access to treatment, care, and support for people living with cancer around the world, Max CEO, Pat Garcia-Gonzalez is the first recipient of the International Chronic Myeloid Leukemia (CML) Foundation’s ERSAP Prize.
The International CML Foundation awarded our CEO Pat Garcia-Gonzalez with the inaugural ERSAP (Emerging Region Support and Partnership) Prize at the 17th annual John Goldman CML Conference co-sponsored by the iCMLf and the European School of Haematology. The iCMLf Directors and Scientific Advisors selected Pat because of her continued commitment, and The Max Foundation’s aim, to help people face cancer with dignity and hope.
Tim Hughes, iCMLf Chair, stated, “Pat strongly believes that people living with CML have the right to access the best possible treatment and support, wherever they live. This is why she has been so determined to make new drugs for CML fully available to patients in emerging economic regions through access programs, education and global advocacy efforts.”
“I am honored to receive the first ever ERSAP Prize and thank our partners at the International CML Foundation for their recognition.” Pat stated. “I take this award as an opportunity to reflect on how providing access to life-saving treatments to people around the world makes our global community stronger and a more just place to live. There are still so many people around the world who deserve our advocacy and support and we carry out our work on their behalf. This award reignites our commitment for finding innovative solutions to help people face cancer with dignity and hope.”
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 27 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
The Max Foundation and Tanner Pharma Group have partnered to create an innovative distribution model to deliver oncology products to patients in need.
The numbers are in! The Max Foundation is thrilled to announce that Spot On CML, our diagnostic collaboration with Fred Hutchinson Cancer Research Center, has provided free testing to 371 patients across 15 countries in its inaugural year.
